AstraZeneca's respiratory tract infection treatment gets prior status from European Medicines Agency

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 07:52

AstraZeneca said Tuesday its treatment for lower respiratory tract infection caused by the respiratory syncytial virus had received priority status from the European Medicines Agency.

The PRIME (PRIority MEdicines) initiative offered proactive and enhanced support to developers of promising medicines to optimise development plans and accelerate evaluation so these medicines can reach patients faster.

This was the first EMA PRIME eligibility that AstraZeneca had received since the programme's initiation in 2016.

'We are excited to receive PRIME eligibility for MEDI8897, our next-generation monoclonal antibody targeting respiratory syncytial virus in infants. We will work closely with the European Medicines Agency to optimise our development plan and help us bring MEDI8897 to patients as quickly as possible,' said Mene Pangalos, Executive Vice-President, R&D BioPharmaceuticals.


Related content

Stocks, bonds and sterling react as markets hope for break in Brexit deadlock

Markets had been taking their lead from the opinion polls and pricing in a clear-cut victory for the Conservative Party and that is what they...

Fri, 13/12/2019 - 13:49


Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC

Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8400p (from 8300p).

Broker Forecasts data provided...

Thu, 12/12/2019 - 08:30


AstraZeneca non-small cell lung cancer drug receives marketing rights in China

AstraZeneca said that its drug to treat patients with non-small cell lung cancer had received marketing authorisation from China's National Medical Products Administration.

The approval...

Thu, 12/12/2019 - 07:45


AstraZeneca, Daiichi Sankyo report positive trial results for breast cancer treatment

AstraZeneca and Daiichi Sankyo released positive data from the a trial of a treatment for breast cancer.

The phase-two trial studied the effects of trastuzumab...

Wed, 11/12/2019 - 13:05


AstraZeneca agrees to sell rights to schizophrenia, bipolar disorder drugs to Cheplapharm for up to $41m

AstraZeneca said it had agreed to sell the commercial rights to its schizophrenia and bipolar disorder drugs in the US and Canada to Cheplapharm Arzneimittel...

Tue, 03/12/2019 - 08:04